TrialAnnals of hematology2017

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.

Alessandro Maria Vannucchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.